



**Maidstone and
Tunbridge Wells**
NHS Trust

Ref: FOI/GS/ID 7305

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

31 May 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Hereditary Angioedema.

You asked:

Q1. In the past 6 months (latest 6 months available) how many patients have received the following Immunoglobulin treatments (for any disease):

- a. Cutaquig*
- b. Cuvitru*
- c. Gammanorm*
- d. Hizentra*
- e. Hyqvia*
- f. Subgam*
- g. Privigen*
- h. Octagam*
- i. Intratect*
- j. Gamunex*
- k. Kiovig*
- l. Panzyga*
- m. Iqymune*
- n. Gammaplex*

Q2. In the past 6 months (latest 6 months available) how many patients have received the following treatments (for any disease):

- a. Berinert (Human C1-esterase inhibitor)*
- b. Cinryze (Human C1-esterase inhibitor)*
- c. Firazyr (Icatibant injection)*
- d. Orladeyo (Berotralstat)*
- e. Ruconest (Recombinant Human C1-esterase inhibitor)*
- f. Takhzyro (Lanadelumab)*

Q3. In the past 2 years, how many patients have been diagnosed (primary and secondary) with Hereditary Angioedema (ICD-10 code D84.1)

Q4. For the patients identified in Q3 above, how many patients have been treated (for any condition) in the past 6 months with the following drugs:

- a. Danazol
- b. Oxandralone
- c. Stanozolol

Trust response:

Q1. Figures for finance months 7-12 2021/22

- a. 0
- b. 0
- c. 1
- d. 4
- e. 0
- f. 0
- g. 94
- h. 9
- i. 10
- j. 11
- k. 71
- l. 5
- m. 1
- n. 0

Q2. Figures for finance months 7-12 2021/22

- a. 0
- b. 0
- c. 0
- d. 0
- e. 0
- f. 0

Q3. 8 all in a secondary position.

Q4. The Pharmacy Team cannot see any of these drugs being dispensed from the hospital pharmacy.